A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc and Copper (Supplement) in this randomized controlled trial publication.

ATN-224 (choline tetrathiomolybdate) is an oral Cu(2+)/Zn(2+)-superoxide dismutase 1 (SOD1) inhibitor with preclinical antitumor activity.

The objective of this study was to screen its clinical activity in patients with biochemically recurrent hormone-naïve prostate cancer.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, men only.

Endpoints included the proportion of patients who were free of PSA progression at 24 weeks, changes in PSA slope/PSADT, and safety.

The study was not powered to detect differences between the 2 treatment groups.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

What Was Measured

Topics PubMed links to this paper include Diarrhea, Disease Progression, Disease-Free Survival, Enzyme Inhibitors, Fatigue, Kaplan-Meier Estimate and Leukopenia.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (Urologic oncology), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Copper (Supplement) compound page, all human trials.